Stablecoins are here to stay says BlackRock
Investing.com - Citizens JMP analyst Jason Butler reiterated a Market Outperform rating and $37.00 price target on Acadia Pharmaceuticals (NASDAQ:ACAD) following the company’s inaugural R&D Day.
The firm highlighted what it views as a "broad and underappreciated pipeline" across CNS and rare diseases that Acadia showcased during Wednesday’s event. Acadia reiterated expectations for combined revenue from DAYBUE and NUPLAZID to exceed $1 billion this year, signaling ongoing commercial strength. This target appears achievable given the company’s impressive 22.4% revenue growth over the last twelve months, as reported by InvestingPro.
Citizens JMP anticipates results from two key programs in the coming months, including the Phase 3 trial for ACP-101 in Prader-Willi syndrome expected in early 4Q25 and Phase 2 results for ACP-204 in Alzheimer’s Disease psychosis projected for mid-2026.
The company detailed several novel development programs during the R&D Day, which Citizens JMP believes supports confidence in diversified drivers of long-term growth for Acadia Pharmaceuticals.
Management noted the blockbuster potential of each asset in its pipeline, emphasizing that potential peak sales for the disclosed pipeline could reach $12 billion, according to information presented at the event. With a current market capitalization of $3.77 billion and a strong balance sheet showing more cash than debt, InvestingPro analysis suggests the stock is currently trading below its Fair Value, presenting a potential opportunity for investors.
In other recent news, Acadia Pharmaceuticals has outlined ambitious plans to initiate seven Phase 2 or Phase 3 clinical studies between 2025 and 2026, with five late-stage study readouts expected through 2027. The company anticipates its commercial portfolio to generate over $1 billion in net sales this year. In a significant development, the U.S. Court of Appeals upheld Acadia’s patent for NUPLAZID, ensuring the drug’s market exclusivity. RBC Capital has raised its price target for Acadia Pharmaceuticals to $38, citing a strong commercial pipeline and cash flow sustainability. The firm maintains an Outperform rating, noting potential growth for NUPLAZID and Daybue. Cantor Fitzgerald continues to rate Acadia as Overweight, highlighting the company’s strategic expansion of its field force to enhance Daybue’s market presence. Additionally, Macquarie has recognized the partnership between Neuren Pharmaceuticals and Acadia, noting potential European approval of Daybue in 2026. Acadia’s ongoing efforts in research and development and strategic market positioning are crucial elements in its growth trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.